|
Market Closed -
Nasdaq
07:00:00 16/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 508.75 USD | +2.06% |
|
+0.62% | +12.22% |
| 15/10 | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| 10/10 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
| Market Cap | 129B 115B 107B 97.31B 183B 12,213B 186B 1,285B 503B 6,372B 484B 474B 20,391B | P/E 2026 * |
34x | P/E 2027 * | 27.4x |
|---|---|---|---|---|---|
| Enterprise Value | 123B 110B 102B 93.12B 175B 11,688B 178B 1,230B 481B 6,098B 463B 453B 19,514B | EV / Sales 2026 * |
9.3x | EV / Sales 2027 * | 8.2x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Tradegate
| VX1 | Real-time | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
Xetra
| VX1 | Delayed | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
London S.E.
| 0QZU | Delayed | |
|
CBOE
| 0QZU | Real-time | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
CBOE
| Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +2.06% | ||
| 1 week | +0.62% | ||
| Current month | -2.69% | ||
| 1 month | -2.07% | ||
| 3 months | +6.81% | ||
| 6 months | +14.51% | ||
| Current year | +12.22% |
| 1 week | 484.08 |  | 517.68 |
| 1 month | 484.08 | | 529.89 |
| Current year | 412.27 | | 560.25 |
| 1 year | 403.16 | | 560.25 |
| 3 years | 341.9 | | 560.25 |
| 5 years | 177.71 | | 560.25 |
| 10 years | 71.46 | | 560.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/04/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 10/04/2019 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 01/01/1998 |
Jeffrey Leiden
CHM | Chairman | 70 | 01/05/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 18/06/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/8/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 27/8/26 | Don | Director | -6,000 | 0.0024% | ||
| 21/7/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.06% | +0.62% | +23.42% | +37.13% | 126B | |
| +3.55% | +5.29% | +54.07% | +105.45% | 1,077B | |
| -0.25% | -2.00% | +32.71% | +61.48% | 612B | |
| +0.59% | +4.44% | +23.69% | +91.54% | 501B | |
| -1.48% | +1.68% | +71.42% | +39.59% | 364B | |
| +2.37% | +5.47% | +32.67% | +48.87% | 353B | |
| +2.64% | +4.90% | +21.01% | +43.85% | 278B | |
| +3.24% | +4.25% | -0.31% | +15.71% | 251B | |
| +1.86% | +5.07% | +47.70% | +52.77% | 230B | |
| +2.49% | +7.16% | +32.82% | +102.67% | 190B | |
| Average | +1.71% | +1.63% | +33.92% | +59.91% | 398.29B | |
| Weighted average by Cap. | +1.75% | +1.49% | +38.57% | +70.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.27B 11.84B 11.01B 10.01B 18.84B 1,257B 19.18B 132B 51.73B 656B 49.79B 48.74B 2,098B | 14.56B 13B 12.08B 10.99B 20.68B 1,380B 21.05B 145B 56.79B 720B 54.66B 53.5B 2,303B |
| Net income | 3.88B 3.47B 3.22B 2.93B 5.51B 368B 5.61B 38.71B 15.15B 192B 14.58B 14.27B 614B | 4.89B 4.36B 4.05B 3.69B 6.94B 463B 7.06B 48.7B 19.06B 242B 18.34B 17.95B 773B |
| Net Debt | -5.54B -4.95B -4.6B -4.18B -7.87B -525B -8.01B -55.25B -21.62B -274B -20.81B -20.37B -877B | -9.58B -8.55B -7.95B -7.23B -13.6B -908B -13.85B -95.49B -37.36B -474B -35.96B -35.2B -1,515B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/10/26 | USD 508.75 | +2.06% | 2,238,894 |
| 14/10/26 | USD 498.50 | +2.74% | 2,090,487 |
| 13/10/26 | USD 485.22 | -4.30% | 1,187,510 |
| 12/10/26 | USD 507.00 | -0.60% | 952,749 |
| 09/10/26 | USD 510.08 | +1.36% | 1,480,861 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
